Nutriband Inc. (NASDAQ:NTRB) Sees Large Growth in Short Interest

Nutriband Inc. (NASDAQ:NTRB - Get Free Report) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 361,000 shares, an increase of 37.7% from the January 31st total of 262,100 shares. Approximately 7.1% of the shares of the company are short sold. Based on an average daily trading volume, of 202,200 shares, the short-interest ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

Separately, Noble Financial started coverage on shares of Nutriband in a report on Wednesday, January 22nd. They issued an "outperform" rating and a $13.00 price objective for the company.

Institutional Investors Weigh In On Nutriband

A hedge fund recently bought a new stake in Nutriband stock. Haven Private LLC purchased a new stake in shares of Nutriband Inc. (NASDAQ:NTRB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 11,561 shares of the company's stock, valued at approximately $54,000. Haven Private LLC owned 0.10% of Nutriband at the end of the most recent reporting period. 19.70% of the stock is currently owned by institutional investors.

Nutriband Trading Down 5.5 %

Shares of NTRB stock traded down $0.38 on Friday, hitting $6.51. 62,187 shares of the company's stock traded hands, compared to its average volume of 83,265. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.83 and a current ratio of 4.96. Nutriband has a one year low of $2.22 and a one year high of $11.78. The company's fifty day simple moving average is $6.34 and its 200 day simple moving average is $5.64. The stock has a market capitalization of $72.30 million, a price-to-earnings ratio of -9.17 and a beta of 1.12.

Remove Ads

Nutriband (NASDAQ:NTRB - Get Free Report) last released its earnings results on Tuesday, December 3rd. The company reported ($0.12) EPS for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%. Equities analysts forecast that Nutriband will post -0.6 EPS for the current year.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.